Immunization

According to the investigators, Streptococcus pneumoniae and non-typeable Haemophilus influenzae are dominant pathogens of otitis media after birth.

Serotype 19A is still the most prevalent serotype for pneumococcal disease, with study authors calling for additional studies to determine the full burden of invasive pneumococcal disease.

The vaccine provides treatment prevention for individuals that are high risk of exposure to the chikungunya virus.

Both newly approved shots possess activity against subvariant EG5.1, which represents an estimated 21.5% of currently circulating variants

Individuals that are younger in age, Black, have low levels of education, and low income were associated with a lower chance of getting the flu shot each year.

Oldest adults should be prioritized for vaccinations as they remain high risk for severe conditions if infected.

Arexvy shows efficacy in helping protect adults aged 50 to 59 years with an increased risk for respiratory syncytial virus lower respiratory tract disease.

RSV can create a problematic infection among children 12 months of age or younger, older adults, and in patients with immunocompromised conditions.

Penbraya (Pfizer Inc) is the first and only approved pentavalent vaccine that confers protection against the most common meningococcal serogroups—A, B, C, W-135, and Y, in individuals 10 through 25 years of age.

An overview of updated CDC ACIP recommendations for COVID-19 vaccines available through commercial channels for the 2023-2024 season.

In a recent study, approximately 99% of children who received solid organ transplant and live vaccination against rubella had antibodies 1 to 3 months post-vaccination.

Understanding the recommended ages for vaccination is crucial to properly advise patients and parents who have questions

Engaging technicians in immunizations has been crucial to public health

Investigators suggest that the Bacille Calmette–Guérin vaccine, which prevented tuberculosis in nonhuman primates infected with SIV, can also protect against HIV.

The clinical trial success in canines may have broader implications for applicability.

mRNA-1083 (Moderna) was found comparable to the standard dose of Fluarix (GSK) in adults aged 50 to 64 years and Fluzone HD ( Sanofi) for influenza and Spikevax (Moderna) for COVID-19.

NVX-CoV2601 vaccine adjuvanted 2023-2024 formula granted EUA for the prevention of COVID-19 in those 12 years of age and older.

Similarly, the results of a survey by the National Foundation for Infectious Diseases demonstrated that approximately 23% were worried about COVID-19 and 19% for respiratory syncytial virus.

Katalin Karikó, PhD, and Drew Weissman, MD, PhD, win Nobel Prize for discoveries in the area of nucleoside base modifications that enabled the development of effective mRNA vaccines against COVID-19.

Most patients had improved clinical response within 90 days of receiving the dendritic cell vaccine and ASCT.

With respiratory syncytial virus vaccine development for infants and children proceeding slowly, therapeutic developers have focused on passive immunity

Pharmacists play a vital role in providing education and administering influenza, COVID-19, and RSV Vaccines

Combining strong evidence-based recommendations with caring, compassionate, and frequent counseling opportunities hopefully will increase vaccine acceptance and ultimately reduce the incidence of HPV and associated cancers among our patients.

Experts answer questions on influenza vaccines.

Community pharmacies and organizations can collaborate to tailor strategies and interventions and address the challenges and specific needs of the community.

Expert panelists addressed concerns about the COVID-19 vaccine costs, availability, efficacy, and timing.

By educating their patients on the provisions of the Inflation Reduction Act, pharmacists can have an even greater impact by increasing vaccine uptake in historically underserved groups.

Compared with COVID-19 vaccination alone, recent study findings show health care workers who received both a COVID-19 booster and influenza vaccinations did not have lower immune response or more frequent adverse events.

Evidence-based programs and policies to improve vaccine uptake are necessary for both caregivers and the general public because influenza vaccine coverage remains low for both groups.

The CDC emphasized the need for protein-based vaccine options in endorsing a vote by the Advisory Committee on Immunization Practices for the universal recommendation of the 2023-2024 monovalent, XBB containing COVID-19 vaccines.